Combined Focused Ultrasound and Calcium Hydroxylapatitie Filler for Skin Laxity and Volume Restoration

NCT ID: NCT04176068

Last Updated: 2024-02-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-04-19
• Study Completion Date: 2021-12-01

Brief Summary

Non-invasive treatment options such as focused ultrasound has been used with success for the treatment of skin laxity in various parts of the body including the face, neck, décolletage, arms, buttocks, thighs, and legs. With the increasing demand for greater results, researchers have started combining modalities together such as focused ultrasound and intradermal filler, with promising effects for skin laxity and volume restoration. This study aims to elucidate the efficacy and added benefits of a combination therapy using focused ultrasound (Ulthera) and calcium hydroxylapatite (Radiesse) for the treatment of skin laxity and volume restoration of the lower thighs, specifically the lower anterior third of the thigh.

Conditions

Skin Laxity

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Combined microfocused ultrasound and calcium hydroxylapatite

One-time intense microfocused ultrasound with calcium hydroxylapatite injection to one anterior lower thigh with option for additional filler injection at 6 weeks, 12 weeks, and 24 weeks. Optional combined treatment of the opposite lower anterior thigh at week 24 with no further follow up.

Group Type: EXPERIMENTAL

calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)

Intervention Type: COMBINATION_PRODUCT

Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.

Interventions

calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)

Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.

Intervention Type: COMBINATION_PRODUCT

Other Intervention Names

intense microfocused ultrasound

Eligibility Criteria

Inclusion Criteria

1. Exhibit skin aging and laxity that will benefit from treatment as determined by the investigator/physician.

2. Subjects between the ages of 18-85 years old, at the time of consent.

3. Subjects may be male or female.

4. Subjects can be of any Fitzpatrick Skin type (I-VI).

5. Subjects must be able and willing to give written informed consent and to comply with the requirements of this protocol. The consent form has been standardized in English. For those patients who do not read and understand English, a consent form will be standardized and provided in a language that they read and understand.

Exclusion Criteria

1. Children and adolescents (less than 18 years old).

2. Subjects who are not willing or able to provide written consent.

3. Individuals with any significant medical history including skin disorders and eating disorders as determined by the investigator/physician.

4. Subjects on any substances affecting blood coagulation (including but not limited to aspirin and other non-steroid anti-inflammatory drugs, warfarin, vitamin E, fish oil, heparin, low-molecular weight heparin, novel anti-coagulants).

5. Subjects with known blood coagulopathies.

6. Subjects with a compromise of local blood supply (including but not limited to recent surgery, severe scarring, autoimmune diseases involving the lower thigh such as lupus, morphea, sarcoid or mixed connective tissue disease).

7. Subjects who have received any treatment for skin laxity or liposuction in the last 12 weeks.

8. Subjects who have experienced an increase or decrease in body weight of more than 10% in the past 24 weeks.

9. Subjects who have a known hypersensitivity reaction to calcium hydroxylapatite or the components of the filler product.

10. Subjects with open wounds in the area of ultrasound treatment.

11. Subjects with pacemakers and/or electronic device implants in the area of ultrasound treatment.

12. Female patients who are planning a pregnancy, currently pregnant or nursing.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of California, Irvine

OTHER

Sponsor Role: lead

Responsible Party

Natasha Mesinkovska

Vice Chair of Clinical Research, Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Natasha Mesinkovska, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, Irvine

Locations

University of California, Irvine Dermatology Clinical Research Center

Irvine, California, United States

Countries

United States

Other Identifiers

20184856

Identifier Type: -

Identifier Source: org_study_id